scholarly journals LONG-TERM SURVIVAL AFTER MULTIPLE SYNOVIAL SARCOMA LUNG-METASTASIS RESECTIONS

2008 ◽  
Vol 69 (8) ◽  
pp. 1897-1901
Author(s):  
Yoshitsugu YAMADA ◽  
Rieko KITAGAWA ◽  
Takemichi SUTO ◽  
Daisuke KIMURA ◽  
Takao TSUSHIMA ◽  
...  
Keyword(s):  
Synovial Sarcoma ◽  
Lung Metastasis ◽  
Term Survival ◽  
Long Term Survival

scholarly journals A patient with a pancreatic metastasis from synovial sarcoma with long-term survival following resection

Suizo ◽  
2020 ◽  
Vol 35 (4) ◽  
pp. 361-369
Author(s):  
Yuko KOBASHI ◽  
Junichi MATSUI ◽  
Yutaka TAKIGAWA ◽  
Takayuki SUZUKI ◽  
Koichi MASUDA ◽  
...  
Keyword(s):  
Synovial Sarcoma ◽  
Pancreatic Metastasis ◽  
Term Survival ◽  
Long Term Survival

scholarly journals The Diameter of Bronchial Resection Margin is Associated With Postoperative Lung Metastasis and Long-term Survival

2020 ◽  
Author(s):  
Zengtuan Xiao ◽  
Mengzhe Zhang ◽  
Xiaofei Wang ◽  
Jialin Gong ◽  
Zuo Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Risk Factor ◽  
Lung Metastasis ◽  
Independent Risk Factor ◽  
Resection Margin ◽  
Primary Lung Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Bronchial Resection

Abstract BackgroundTo investigate the significance of the diameter of bronchial resection margin (DBRM) on the postoperative lung metastasis and long -term survival of patients with primary lung cancer.MethodsWe retrospectively analyzed the data of 1844 patients with primary lung cancer between January 2006 and December 2010 after surgery. Patients were divided into DBRM≤1 cm group (826 patients) and DBRM>1 cm group (1018 patients). Propensity score matching was used to reduce grouping selection bias. Furthermore, we divide the 974 patients who had definite first metastasis site into lung metastasis group (283 patients) and other metastasis group (691 patients), and analyzed related risk factors and prognosis of metastasis. Disease-free survival and overall survival were the study end points.ResultsThe DBRM≤1 cm group had a significantly better prognosis than DBTM>1 cm group (5-year DFS, 36.5% vs 25.7%; P < 0.001; 5-year OS, 45.4% vs 34.1%; P < 0.001). After multivariate survival analysis, DBRM remained the independent favorable effect on DFS (HR, 1.198; 95% CI, 1,071 to 1.340; P = 0.002) and OS (HR, 1.186; 95% CI, 1.060 to1.327; P = 0.003). PSM further confirmed that DBRM≤1 cm group had a better DFS (P = 0.032) and OS (P = 0.026) than the DBRM>1 cm group. It revealed that the DBRM was an independent risk factor for postoperative lung metastasis, and postoperative adjuvant therapy could improve the OS of lung metastases.ConclusionsThe DBRM was an independent risk factor for postoperative lung metastasis and adjuvant therapy could improve long-term survival.

scholarly journals Long-term survival (>20 years) after hepatic epithelioid hemangioendothelioma and lung metastasis without any specific treatment: A case report

Kanzo ◽  
2018 ◽  
Vol 59 (12) ◽  
pp. 692-699
Author(s):  
Shota Yamaguchi ◽  
Mamiko Tsukui ◽  
Kouichi Miura ◽  
Naoki Morimoto ◽  
Toshiya Ohtake ◽  
...  
Keyword(s):  
Case Report ◽  
Lung Metastasis ◽  
Specific Treatment ◽  
Epithelioid Hemangioendothelioma ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-Term Survival of Rectal Cancer With Lung Metastasis–A Case Report of Possible Metronomic Effect of Tegafur-Uracil

2019 ◽  
Vol 104 (9-10) ◽  
pp. 494-498
Author(s):  
Tzu-Chi Hsu ◽  
Ming-Jen Chen
Keyword(s):  
Rectal Cancer ◽  
Ct Scan ◽  
Lung Metastasis ◽  
Lung Lesion ◽  
Lung Field ◽  
Term Survival ◽  
Long Term Survival ◽  
Living Well ◽  
The Moment

Background A 76-year-old woman underwent a low anterior resection in May 2000 for a moderately differentiated Dukes' C adenocarcinoma of rectum. She started to take futraful and leucovorin as adjuvant chemotherapy after surgery. A chest X-ray taken 7 months later was reported as having an irregular soft tissue nodule in right middle lung field. A subsequent computerized tomography (CT) scan of chest confirmed the lesion. A thoracotomy was suggested; however, the patient refused surgery. She also refused needle biopsy of the lung lesion for making a definite diagnosis. Case summary The patient had been continuously taking futraful and leucovorin as chemotherapeutic agent; in July 2001 she was switched to tegafur-uracil (UFUR) and leucovorin. She was admitted in October 2005 for shortness of breath. After conservative management, her condition improved and she was discharged. The patient still refused any workup for tissue diagnosis and any further aggressive treatment. Since then, she had been continuously taking UFUR and leucovorin then. An abdominal CT scan of in December 2009 was negative for metastasis. Several ultrasound examinations were also reported as having no metastasis in the follow-up period. A chest CT scan did show slow enlargement of the lung metastasis. Her carcinoembryonic antigen level was 3.85 ng/mL prior to surgery, and then fluctuated between 2.42 ng/mL and 6.34 ng/mL. In spite of progressive enlargement of the mass in her lung, the patient is asymptomatic and living well by herself. The only medication she is taking at the moment is UFUR and leucovorin. Conclusions This case suggested that long-term survival could be observed in a patient with metastatic disease from rectal cancer without aggressive chemotherapy. The metronomic effect of UFUR and leucovorin might be contributory to the patient's long-term survival. Elevation of CEA level is not necessarily observed with the presence and progress of metastasis of rectal cancer.

Treatment failure in endometrial cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16537-e16537
Author(s):  
Yun-hsin Tang ◽  
Angel Chao ◽  
Chyong-Huey Lai ◽  
Cheng-Tao Lin ◽  
Gingin Lin ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Treatment Failure ◽  
Lung Metastasis ◽  
Ca 125 ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival ◽  
Definitive Surgery

e16537 Background: To evaluate the clinical features and the outcomes of endometrial cancer with treatment failure after primary definitive surgery. Methods: A total of 89 patients who received primary definitive surgery between 2000 and 2010 with treatment failure were retrospectively reviewed. The correlation of clinicopathological features, primary treatment, failure pattern, and salvage treatment with outcomes were analyzed. Results: Twenty of the 89 patients with persistent or progressive diseases died at a median of 7.6 months (range, 1.9-14.0 months). The remaining 69 patients with initial disease controlled but subsequent relapse had a median time to recurrence of 13.9 months (range, 3.2 – 97.1). Assessable failure patterns included vaginal only in 14.5%, pelvic in 2.9%, distant in 59.4%, distant and loco-regional in 23.2%. The median survival after recurrence (SAR) was 25.5 months (range 1.5-121.7 months). The 5-year SAR rate was 52.7%. By univariate analysis, FIGO stage, grade of differentiation, histologic cell type, cervical invasion, adnexal metastasis, and status of lymph node metastasis when initial diagnosis, and bone or/and lung metastasis, radiotherapy after recurrence, and CA-125 ≥ 35 U/mL at recurrence were significant factors of 5-year survival after recurrence. By multivariate analysis, high-grade cancer (HR 3.05, 1.17-8.01; p = 0.023), bone and/or lung metastasis at recurrence (HR2.81, 1.15-6.85; p = 0.023), and CA-125 ≥ 35 U/mL (HR 2.85, 1.18-6.87; p = 0.013) were significantly poor prognostic factors for SAR. Six patients achieved long-term survival with more than one recurrence after aggressive multimodal salvage therapy along with deliberate restaging and post-therapy surveillance. Conclusions: High-grade, bone and/or lung metastasis and CA-125 ≥ 35 U/mL at recurrence were significantly poor prognostic factors for SAR. After intensive treatment, patients with recurrent endometrial cancer may have long-term survival.

Sign in / Sign up

Export Citation Format

Share Document